Maurice was discovered this morning pacing his trading desk in concentric circles, occasionally hurling banana peels at a printed earnings calendar while muttering about “the tyranny of sell-the-news moments.”
Here’s something I’ve learned in my seventeen years analyzing market behavior through a primate lens: the stock market is fundamentally broken at celebrating good news. It’s like inviting someone to a surprise party and then being shocked when they’re surprised. Last month, Rocket Pharmaceuticals (RCKT) received FDA accelerated approval for KRESLADI—a gene therapy for severe Leukocyte Adhesion Deficiency-1, a devastating immune disorder in children—and the stock got absolutely obliterated. Down nearly 9% on what should have been a confetti moment.
Now, I’m looking at this wreckage, and I’m genuinely excited. Not in the way I get excited about a fresh banana. This is different. This is the kind of setup where Foxy’s instincts—and yes, I’m taking Foxy seriously here—actually makes mathematical sense.
Let me explain why a late-stage biotech company trading at $3.61 after clinching a major regulatory win might be the most asymmetric opportunity I’ve seen in the gene therapy space in six months.
The Setup: A Gene Therapy Company Doing the Thing Gene Therapy Companies Are Supposed To Do
Rocket Pharmaceuticals isn’t a concept. It’s not a PowerPoint presentation masquerading as a company. It’s a 25-year-old biotechnology outfit headquartered in Cranbury, New Jersey, with a focused pipeline in genetic disorders where—and this matters—there are essentially no good existing treatments. We’re talking about diseases where the current standard of care is basically “hope your immune system doesn’t completely betray you,” which, spoiler alert, it does.
The company runs two distinct programs: in vivo AAV therapies (delivered directly to the patient’s body) and ex vivo lentiviral therapies (you harvest cells, fix them in a lab, put them back). Think of it like the difference between calling a plumber to fix your pipes versus rebuilding your entire plumbing system in advance. Both strategies matter because some diseases respond better to one approach than the other.
On the in vivo side, they’ve got RP-A501 for Danon disease (Phase 2), which attacks the heart directly. On the lentiviral side—the one that just won FDA approval—is KRESLADI for LAD-1, a condition where children’s immune systems can’t properly respond to infections because their white blood cells can’t stick to vessel walls. It’s brutal. It’s rare. It’s exactly the kind of disease gene therapy was invented to address.
So KRESLADI got accelerated approval. Fantastic. Company pops 8.9% in the opposite direction. Market logic:
“Good news? Must be priced in. Or worse—we’re actually concerned about manufacturing scale, reimbursement uncertainty, and the fact that LAD-1 is incredibly rare, so peak sales might only be $150 million, which sounds great until you’re a biotech company that’s burned through $100+ million per year for a decade.”
And they’re not wrong about those concerns. But here’s where they ARE wrong.
The Banana Peel Principle: Slipping on the Obvious While Missing the Whole Bunch
Markets sometimes confuse “difficult” with “impossible.” Rare disease therapeutics ARE difficult. The patient populations are tiny. Reimbursement is complicated. Manufacturing gene therapies at scale is not something you learn from a YouTube tutorial. But—and this is crucial—Rocket isn’t betting its entire existence on one Hail Mary therapy. KRESLADI is the first fruit on the tree. The tree has other branches.
Look at their pipeline. Fanconi Anemia (RP-L102) is in development. Pyruvate Kinase Deficiency (RP-L301) is in development. And then there’s the cardiac program: Danon disease (RP-A501, Phase 2), PKP2-Associated Cardiomyopathy (RP-A601, Phase 1), and BAG3 Dilated Cardiomyopathy (preclinical). Now, the cardiac stuff is further out. But here’s the thing that matters: if you prove your gene therapy technology works in one disease—which KRESLADI just did—you’ve proven the engineering works. The remaining question isn’t “can we do this?” It’s “will it work for THIS disease?” Those are fundamentally different questions. One gets answered in FDA committees. The other gets answered through your actual ability to execute.
KRESLADI proved Rocket can execute.
The market is treating this like a lottery ticket that didn’t win. Instead, it’s more like proof that the lottery ticket printer actually works.
The Financial Skeleton: Why Low Beta Matters When Everything Else Is Terrifying
Let’s talk about the financial picture, because this is where things get genuinely interesting.
Market cap: $392 million. Cash runway is absolutely the question here, and I’m not going to pretend it isn’t. Free cash flow is massively negative (negative $104 million last reported period), which means they’re burning cash faster than a monkey can peel a banana. The debt-to-equity ratio sits at 8.97, which sounds alarming until you realize that biotech companies routinely carry high debt because investors are betting on future value, not current earnings.
Here’s what actually matters: they just got FDA approval for a revenue-generating therapy. KRESLADI isn’t a Phase 2 candidate in some distant future. It’s an approved drug that can generate revenue starting now. LAD-1 is rare (maybe 2,000 patients in the US), but reimbursement for gene therapies in rare diseases is actually pretty good because insurers understand there’s no alternative. A single KRESLADI treatment probably runs $2-3 million. Even at modest penetration—let’s say 15% of addressable patients in year one—you’re looking at $90-180 million in revenue, which meaningfully extends the runway and changes the cash burn calculus.
And that’s just one therapy. Just the first one.
The beta of 0.574 is the quiet hero here. Foxy specifically called this out, and for good reason. In a volatile biotech sector, Rocket doesn’t move with the market like other genomics or therapeutics plays do. That means when the sector gets walloped, RCKT doesn’t get walloped as hard. When things go well, it won’t rocket up as much either—but we’re not looking for a 500% move. We’re looking for a 2-3 year journey where revenue actually materializes and the market reprices the risk downward.
The Catalyst Calendar: When the Confetti Actually Lands
Here’s what I find compelling about Foxy’s thesis, and why I’m not dismissing this as “another biotech lottery.”
We’ve got clinical readouts coming. RP-A501 for Danon disease is in Phase 2. That’s probably 18-24 months away from meaningful data. If that works, you’re talking about a cardiac indication—a much larger market than LAD-1. Cardiac diseases affect millions. LAD-1 affects thousands. The market currently isn’t pricing in the probability that a company that just proved it can do this ONCE will be able to do it again in a larger indication.
Additionally, the gene therapy regulatory environment has warmed considerably post-2024. The FDA has approved more gene therapies for rare diseases than ever before. The entire sector got a congressional and regulatory push. Rocket isn’t fighting headwinds anymore; it’s sailing with the current.
Between now and 2027, we’re likely to see:
— KRESLADI’s initial commercial traction (patients getting treated, real-world data emerging)
— Phase 2 readout for Danon disease (RP-A501)
— Potential expansion of KRESLADI into European markets
— Phase 1 data or advancement for PKP2-ACM cardiac therapy
Each of these is a possible repricing event. And here’s the asymmetry: if LAD-1 was a fluke and these other candidates fail, sure, the stock probably goes to $0.50. But if even ONE of the cardiac candidates shows promise, and the market realizes Rocket has a pipeline with multiple shots on goal, this stock easily doubles from here. Easily. The KRESLADI approval already proved they can navigate FDA approval successfully.
The Risks (Yes, They’re Real)
I’m not going to pretend this is a safe investment. Let me be clear: this is exactly what Foxy described—high risk. The short ratio is 4.64%, which means shorts are circling. They’re not wrong to be skeptical. Gene therapy manufacturing is genuinely hard. Clinical outcomes could disappoint. Reimbursement could be worse than expected. And the most important risk: cash runway.
Even with KRESLADI revenue coming in, Rocket is a cash-burn machine. If the company miscalculates commercialization, if manufacturing scaling goes wrong, if clinical data disappoints—the stock could be underwater fast. The negative forward P/E ratio (-2.70) tells you exactly what the current market expects: losses. The company isn’t profitable, and nobody thinks it will be for years.
Also worth noting: the recent stock decline happened despite the FDA approval. That’s not a coincidence. It suggests the market was already skeptical before the approval and used it as an exit opportunity. That’s actually more honest, in a weird way. It means the really bearish people have already left, and you’re not catching falling knives. You’re looking at the aftermath of the knife landing.
Why The Entry Price Matters More Than The Target Price
Foxy’s entry price is $3.48. Current price is $3.61. That’s basically here. The target price cited is $6.50 in the initial thesis, though analyst consensus sits at $8.48 (from 11 analysts covering the stock). Look, analyst targets are horoscopes written in Excel, but the fact that 11 analysts are covering a $392 million market cap biotech tells you something: there’s legitimate institutional interest here.
The upside scenario doesn’t require heroics. It just requires:
1) KRESLADI generates meaningful revenue (not a given, but probable)
2) One of the cardiac candidates shows promise in clinical trials
3) The market reprices the risk downward as execution becomes visible
4) Runway extends through inflection point
If all three happen, we’re not talking about lottery odds. We’re talking about a 100-150% return over 24-36 months. That’s not life-changing money, but it’s real money on a $3-ish entry point.
The Wedbush Angle
One analyst (Wedbush, March 3) specifically called out Rocket as “significantly undervalued” with the cardiac pipeline advancing. Wedbush isn’t some cheerleader firm. They actually do work. So when they’re saying “this thing is being priced like it’s worthless when it’s actually sitting on promising cardiac programs,” I listen.
The sell-the-news phenomenon that crushed the stock after KRESLADI approval is classic biotech theater. Sophisticated investors use good news as liquidity to exit. Dumber money panics and follows. By the time real revenue starts flowing, the stock price has already capitulated and the narrative changes from “overhyped” to “this is actually working.”
Rocket might be at that inflection point right now.
My Honest Take
This is not a stock for people who need sleep at night. It’s illiquid (short ratio of 4.64 speaks to bears positioning). It burns cash fast. Gene therapy is complicated. Clinical outcomes could disappoint. Manufacturing could fail. Reimbursement could crater.
But the approval just happened. The pipeline exists. The market hates it for exactly the wrong reasons (rare disease cap on LAD-1 upside, which is true but myopic). And the next catalyst—serious KRESLADI revenue or Danon disease Phase 2 data—could shift sentiment entirely.
Foxy’s thesis is contrarian, but it’s contrarian in a way that actually makes sense. Late-stage biotech, low beta, catalyst-driven. RCKT fits that profile. The question isn’t whether it works—it’s whether the market will eventually price in the working.
My Monkey Momentum Index gives this a 7.1. Not a slam dunk. But a genuine opportunity in a stock that the market has briefly abandoned.
Trained Market Monkey 